Friday, 25 September 2026European Markets

AFFLUENT MEDICAL Stock Impressive Jump Before The Weekend, Outperforms Market

Loading stream...

(vianews) - the market ended the session with affluent medical (afme.pa) jumping 20.9% to €1.62 on friday, following the last session's upward trend. cac 40 rose 0.09% to €7,934.17, following the last session's downward trend on what was a somewhat up trend trading session today.

affluent medical's last close was €1.34, 41.74% under its 52-week high of €2.30.

about affluent medical

affluent medical sa develops minimally invasive medical devices for the treatment of heart and vascular diseases in france. it develops kardiozis technology for the treatment of abdominal aortic aneurysm; kalios and epygon implants to treat mitral insufficiency; and artus implant, an implantable electro-mechanical artificial sphincter for the treatment of severe urinary incontinence in women and men. the company was founded in 2011 and is based in aix-en-provence, france.

earnings per share

as for profitability, affluent medical has a trailing twelve months eps of €-0.65.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -40.37%.

volatility

affluent medical's last week, last month's, and last quarter's current intraday variation average was a positive 1.59%, a negative 1.57%, and a positive 3.83%.

affluent medical's highest amplitude of average volatility was 4.76% (last week), 3.36% (last month), and 3.83% (last quarter).

yearly top and bottom value

affluent medical's stock is valued at €1.62 at 21:32 est, way below its 52-week high of €2.30 and way higher than its 52-week low of €0.93.

revenue growth

year-on-year quarterly revenue growth declined by 16.3%, now sitting on 1.22m for the twelve trailing months.

more news about affluent medical (afme.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Enterprise AI Agents Scale Up Through Partnerships and Funding, But Data Readiness Lags Ambition
A wave of vertical AI-agent startups (Swarm, Veridox, Avallon AI, DA2, F2, Earthian, Meanwhile, Covecta, Penguin AI, Maisa AI) is being funded and profiled just as major infrastructure players — Microsoft/Mistral, Siemens/NVIDIA, and Manulife/Microsoft — cement enterprise AI governance and compute partnerships. Yet a Google Cloud report shows AI agents still lack access to the majority of company data (only 45% on average), and insider selling at incumbent C3.ai signals investor caution even as adoption intent (100% planned agentic AI use within two years) races ahead of actual data infrastructure.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Berkshire Hathaway
Both facts report Berkshire Hathaway's cash position on 2026-01-01 with identical observation timestamps, but claim vastly different values: 380 billion USD vs 400 USD. These cannot both be true for the same entity at the same point in time. The magnitude of the discrepancy (a factor of ~10^9) rules out rounding, unit conversion, or methodological differences.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,984
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,984 facts checked against source5,306 source documents archived
Query this data → isubstrate.com